301 Binney Street
8 articles about Odyssey Therapeutics
Odyssey Therapeutics to Present Data for Three Immunology Programs at American College of Rheumatology Convergence 2023
Odyssey Therapeutics, Inc. will present data highlighting three of its immunology programs at the American College of Rheumatology ( ACR ) Convergence 2023 meeting in San Diego, California, November 10-15, 2023.
Odyssey Therapeutics, Inc. today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer.
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
While Biogen and Seagen made the biggest C-suite splashes this week, other companies across the biopharma industry also bolstered their leadership teams with new talent.
Odyssey Therapeutics Expands Management Team with Key Appointments in Research Development and Strategy
Odyssey Therapeutics, Inc. today announced the appointment of Jeff Hermes, Ph.D., as Executive Vice President of Enabling Sciences and promotion of Natalie Dales, Ph.D., to the newly created position of Chief of Research Operations and Portfolio Strategy.
Odyssey Therapeutics raised $168 million in a Series B financing round, which will be used to advance its portfolio of immunomodulators and oncology therapies.
Odyssey Therapeutics, Inc., a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, announced a $168 million Series B financing.
Odyssey Therapeutics completed an oversubscribed $218 million Series A round. The funds will be used to advance multiple programs from its pipeline and its discovery platform.